Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001078
UniProt IDP62942
Primary gene name(s)FKBP1A
Synonym gene name(s)FKBP1, FKBP12
Protein namePeptidyl-prolyl cis-trans isomerase FKBP1A
Protein functionKeeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. {ECO:0000269|PubMed:16720724, ECO:0000269|PubMed:9233797}.
Subcellular locationCytoplasm.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P62942
Gene Ontology
(Biological Process)
Complete annatation
'de novo' protein folding [GO:0006458];
amyloid fibril formation [GO:1990000];
calcium ion transmembrane transport [GO:0070588];
chaperone-mediated protein folding [GO:0061077];
cytokine-mediated signaling pathway [GO:0019221];
extracellular fibril organization [GO:0043206];
heart morphogenesis [GO:0003007];
heart trabecula formation [GO:0060347];
muscle contraction [GO:0006936];
negative regulation of protein phosphatase type 2B activity [GO:0032513];
negative regulation of protein phosphorylation [GO:0001933];
positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123];
positive regulation of protein binding [GO:0032092];
positive regulation of protein ubiquitination [GO:0031398];
protein folding [GO:0006457];
protein maturation by protein folding [GO:0022417];
protein peptidyl-prolyl isomerization [GO:0000413];
protein refolding [GO:0042026];
regulation of activin receptor signaling pathway [GO:0032925];
regulation of amyloid precursor protein catabolic process [GO:1902991];
regulation of immune response [GO:0050776];
regulation of protein localization [GO:0032880];
regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314];
release of sequestered calcium ion into cytosol [GO:0051209];
response to caffeine [GO:0031000];
response to iron ion [GO:0010039];
SMAD protein complex assembly [GO:0007183];
T cell activation [GO:0042110];
T cell proliferation [GO:0042098];
transforming growth factor beta receptor signaling pathway [GO:0007179];
ventricular cardiac muscle tissue morphogenesis [GO:0055010]
Gene Ontology
(Molecular Function)
Complete annatation
activin binding [GO:0048185];
FK506 binding [GO:0005528];
ion channel binding [GO:0044325];
macrolide binding [GO:0005527];
peptidyl-prolyl cis-trans isomerase activity [GO:0003755];
signal transducer activity [GO:0004871];
SMAD binding [GO:0046332];
transforming growth factor beta receptor binding [GO:0005160];
type I transforming growth factor beta receptor binding [GO:0034713]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
endoplasmic reticulum membrane [GO:0005789];
extracellular exosome [GO:0070062];
extracellular matrix [GO:0031012];
membrane [GO:0016020];
terminal cisterna [GO:0014802];
Z disc [GO:0030018]
Protein-protein interaction108570
Phylogenetic treeP62942
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.9153270557798060.005481272657008370.0156633411078595
AZA vs. DISU-0.2987096342437410.2374433545850130.821854758571361
AZA vs. IL70.1302317123842740.4975164407431390.999311006273513
AZA vs. SAHA0.1255393830970420.608212859845010.871584813128974
DISU vs. CD3-1.22523337640410.0008449118537792180.00358261639489956
DISU vs. IL70.4191288828553230.09629652020399050.411185083681453
DISU vs. SAHA0.4266282628940880.1451020921145290.489553084902185
DMSO vs. AZA-0.03668119509701080.8264043643448121
DMSO vs. CD3-0.9604448457291410.00286332384045540.00854435428368006
DMSO vs. DISU0.2611071430850710.2842377148262790.798676066834541
DMSO vs. IL70.1737453355633610.3333104852332660.805104240488942
DMSO vs. SAHA0.1562850179171290.5086276684819710.818791667559472
HIV vs. Mock in Activation-0.05181380054414560.9335392354571890.999983755607037
HIV vs. Mock in Latency0.08745602324610060.5964286623944880.999834320637052
IL7 vs. CD3-0.7793614704715050.01573332105191120.043196420439974
SAHA vs. CD3-0.8127539593102670.02250543614539470.0508252544149705
SAHA vs. IL7-0.006257238334693220.979612035600940.992866447767307
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.025872 0.899218
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.069 0.903 0.858 0.995 0.984
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00864 Tacrolimus approved, investigational yes inhibitor
DB01723 {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid experimental unknown unknown
DB02311 Methyl Methylsulfinylmethyl Sulfide experimental unknown unknown
DB02888 FKB-001 experimental unknown unknown
DB03621 L-709,587 experimental unknown unknown
DB04094 4-Hydroxy-2-Butanone experimental unknown unknown
DB00877 Sirolimus approved, investigational yes other
DB00337 Pimecrolimus approved, investigational unknown potentiator
DB05814 GPI-1485 investigational unknown unknown
DB03338 Heptyl-Beta-D-Glucopyranoside experimental unknown unknown
DB01951 Gpi-1046 experimental unknown unknown
DB08231 MYRISTIC ACID experimental unknown unknown
DB08520 (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE experimental unknown unknown
DB01712 (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester experimental unknown unknown
DB08597 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine experimental unknown unknown
DB04012 (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1A7X X-ray 2.0Å A/B=2-108.
1B6C X-ray 2.6Å A/C/E/G=2-108.
1BKF X-ray 1.6Å A=2-108.
1BL4 X-ray 1.9Å A/B=2-108.
1D6O X-ray 1.8Å A/B=2-108.
1D7H X-ray 1.9Å A/B=2-108.
1D7I X-ray 1.9Å A/B=2-108.
1D7J X-ray 1.8Å A/B=2-108.
1EYM X-ray 2.0Å A/B=2-108.
1F40 NMR - A=2-108.
1FAP X-ray 2.7Å A=2-108.
1FKB X-ray 1.7Å A=2-108.
1FKD X-ray 1.7Å A=2-108.
1FKF X-ray 1.7Å A=2-108.
1FKG X-ray 2.0Å A=2-108.
1FKH X-ray 1.9Å A=2-108.
1FKI X-ray 2.2Å A/B=2-108.
1FKJ X-ray 1.7Å A=2-108.
1FKR NMR - A=2-108.
1FKS NMR - A=2-108.
1FKT NMR - A=2-108.
1J4H X-ray 1.8Å A=2-108.
1J4I X-ray 1.8Å A=2-108.
1J4R X-ray 1.8Å A/B/D=2-108.
1NSG X-ray 2.2Å A=2-108.
1QPF X-ray 2.5Å A/D=2-108.
1QPL X-ray 2.9Å A/C=2-108.
2DG3 X-ray 1.7Å A=2-108.
2DG4 X-ray 1.7Å A=2-108.
2DG9 X-ray 1.7Å A=2-108.
2FAP X-ray 2.2Å A=2-108.
2FKE X-ray 1.7Å A=2-108.
2PPN X-ray 0.9Å A=2-108.
2PPO X-ray 1.2Å A=2-108.
2PPP X-ray 0.9Å A=2-108.
2RSE NMR - A=2-108.
3FAP X-ray 1.8Å A=2-108.
3H9R X-ray 2.3Å B=1-108.
3MDY X-ray 2.0Å B/D=1-108.
4DH0 X-ray 2.1Å A=2-108.
4FAP X-ray 2.8Å A=2-108.
4IPX X-ray 1.7Å A=2-108.
4N19 X-ray 1.2Å A=2-108.
4ODP X-ray 1.7Å A=85-97.
4ODQ X-ray 2.0Å A=85-97.
4ODR X-ray 1.9Å A/B=85-97.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 binds 9546659

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found